Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

被引:577
作者
Moise-Broder, PA
Forrest, A
Birmingham, MC
Schentag, JJ
机构
[1] CPL Assoc, LLC, Amherst, NY 14226 USA
[2] Univ Buffalo, Sch Pharm & Pharmaceut Sci, Buffalo, NY 14222 USA
关键词
D O I
10.2165/00003088-200443130-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Vancomycin is commonly used to treat staphylococcal infections, but there has not been a definitive analysis of the pharmacokinetics of this antibacterial in relation to minimum inhibitory concentration (MIC) that could be used to determine a target pharmacodynamic index for treatment optimisation. Objective: To clarify relationships between vancomycin dosage, serum concentration, MIC and antimicrobial activity by using data gathered from a therapeutic monitoring environment that observes failures in some cases. Methods: We investigated all patients with a Staphylococcus aureus lower respiratory tract infection at a 300-bed teaching hospital in the US during a 1-year period. Clinical and pharmacokinetic information was used to determine the following: (i) whether steady-state 24-hour area under the concentration-time curve (AUC(24)) divided by the MIC (AUC(24)/MIC) values for vancomycin could be precisely calculated with a software program; (ii) whether the percentage of time vancomycin serum concentrations were above the MIC (%Time>MIC) was an important determinant of vancomycin response; (iii) whether the time to bacterial eradication differed as the AUC(24)/MIC value increased; (iv) whether the time to bacterial eradication for vancomycin differed compared with other anti-bacterials at the same AUC(24)/MIC value; and (v) whether a relationship existed between time to bacterial eradication and time to significant clinical improvement of pneumonia symptoms. Results: The median age of the 108 patients studied was 74 (range 32-93) years. Measured vancomycin AUC(24)/MIC values were precisely predicted with the A.U.I.C. calculator in a subset of our patients (r(2) = 0.935). Clinical and bacteriological response to vancomycin therapy was superior in patients with higher ( greater than or equal to400) AUC(24)/MIC values (p = 0.0046), but no relationship was identified between vancomycin %Time>MIC and infection response. Bacterial eradication of S. aureus (both methicillin-susceptible and methicillin-resistant) occurred more rapidly (p = 0.0402) with vancomycin when a threshold AUC24/MIC value was reached. S. aureus killing rates were slower with vancomycin than with other anti staphylococcal antibacterials (p = 0.002). There was a significant relationship (p < 0.0001) between time to bacterial eradication and the time to substantial improvement in pneumonia score. Conclusions: Vancomycin AUC(24)/MIC values predict time-related clinical and bacteriological outcomes for patients with lower respiratory tract infections caused by methicillin-resistant S. aureus.
引用
收藏
页码:925 / 942
页数:18
相关论文
共 72 条
[1]   COMPARISON OF RADIOIMMUNOASSAY AND FLUORESCENT POLARIZATION IMMUNOASSAY FOR QUANTITATIVE-DETERMINATION OF VANCOMYCIN CONCENTRATIONS IN SERUM [J].
ACKERMAN, BH ;
BERG, HG ;
STRATE, RG ;
ROTSCHAFER, JC .
JOURNAL OF CLINICAL MICROBIOLOGY, 1983, 18 (04) :994-995
[2]   POPULATION PHARMACOKINETIC METHODS TO OPTIMIZE ANTIBIOTIC EFFECTS [J].
AMSDEN, GW ;
BALLOW, CH ;
SCHENTAG, JJ .
DRUG INVESTIGATION, 1993, 5 (05) :256-268
[3]   ANTIMICROBIAL AGENT SUSCEPTIBILITY PATTERNS OF BACTERIA IN HOSPITALS FROM 1971 TO 1982 [J].
ATKINSON, BA ;
LORIAN, V .
JOURNAL OF CLINICAL MICROBIOLOGY, 1984, 20 (04) :791-796
[4]   Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate-use program [J].
Birmingham, MC ;
Rayner, CR ;
Meagher, AK ;
Flavin, SM ;
Batts, DH ;
Schentag, JJ .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (02) :159-168
[5]   Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus:: Evidence of resistance to vancomycin [J].
Burnie, J ;
Matthews, R ;
Jiman-Fatami, A ;
Gottardello, P ;
Hodgetts, S ;
D'arcy, S .
CLINICAL INFECTIOUS DISEASES, 2000, 31 (03) :684-689
[6]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[7]   Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia:: A meta-analysis [J].
Cosgrove, SE ;
Sakoulas, G ;
Perencevich, EN ;
Schwaber, MJ ;
Karchmer, AW ;
Carmeli, Y .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (01) :53-59
[8]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[9]  
*CTR DRUG EV RES, EV CLIN STUD ANT DIV
[10]   Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy [J].
Drew, RH ;
Perfect, JR ;
Srinath, L ;
Kurkimilis, E ;
Dowzicky, M ;
Talbot, GH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (05) :775-784